A Randomized, Double-Blind, Placebo-Controlled Trial of Moclobemide in Patients With Chronic Fatigue Syndrome
The Journal of Clinical PsychiatryPublished 15 September 2000
Ian B. Hickie, Andrew Wilson, J. Murray Wright, Barbara Bennett, Denis Wakefield, Andrew R. Lloyd
Citations70
SJR quartileQ1
SJR score1.49
SNIP1.38
Generate an AI Snapshot to get a quick, structured summary of this paper.
Study Snapshot
ObjectiveStudy objective
MethodsResearch methodology
PopulationPopulation studied
Sample sizeSample sizes
OutcomesStudy outcomes here
ResultsStudy results comes here
LimitationsResearch study limitations comes here
A concise AI-generated summary of the paper will appear here once you click Generate AI Snapshot.
TL;DR
Moclobemide produces some improvement in key symptoms experienced by patients with chronic fatigue syndrome, not dependent on the presence of concurrent psychological distress and likely to be shared with other monoamine oxidase inhibitors.
Abstract
Moclobemide produces some improvement in key symptoms experienced by patients with chronic fatigue syndrome. This effect is not dependent on the presence of concurrent psychological distress and is likely to be shared with other monoamine oxidase inhibitors.
Keywords
MedicineNeuroscience